Literature DB >> 18707146

Fluorophore labeling enables imaging and evaluation of specific CXCR4-ligand interaction at the cell membrane for fluorescence-based screening.

Wataru Nomura1, Yasuaki Tanabe, Hiroshi Tsutsumi, Tomohiro Tanaka, Kenji Ohba, Naoki Yamamoto, Hirokazu Tamamura.   

Abstract

Development of CXCR4-specific ligands is an important issue in chemotherapy of HIV infection, cancer metastasis, and rheumatoid arthritis, and numerous potential ligands have been developed to date. However, it is difficult to assess their binding mode and specificity because of uncertainties in the structure of the CXCR4-ligand complexes. To address this problem, we have synthesized fluorophore labeled Ac-TZ14011, which is derived from T140, a powerful CXCR4 antagonist. Binding of Ac-TZ14011 to CXCR4 on the cell membrane was observed by fluorescence microscope, and analysis of the binding data produced IC 50 values of several ligands comparable to those obtained in RI-based assays. This fluorescence-based assay is applicable to explore new pharmacophores of CXCR4-specific ligands with high-throughput screening and also to screening of the other GPCR binding ligands.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18707146     DOI: 10.1021/bc800216p

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  12 in total

1.  Time-resolved fluorescence ligand binding for G protein-coupled receptors.

Authors:  Alexander Emami-Nemini; Thomas Roux; Marion Leblay; Emmanuel Bourrier; Laurent Lamarque; Eric Trinquet; Martin J Lohse
Journal:  Nat Protoc       Date:  2013-06-13       Impact factor: 13.491

Review 2.  Multimodality imaging of CXCR4 in cancer: current status towards clinical translation.

Authors:  T R Nayak; H Hong; Y Zhang; W Cai
Journal:  Curr Mol Med       Date:  2013-12       Impact factor: 2.222

Review 3.  Intraoperative imaging in ovarian cancer: fact or fiction?

Authors:  Lucia M A Crane; Marleen van Oosten; Rick G Pleijhuis; Arash Motekallemi; Sean C Dowdy; William A Cliby; Ate G J van der Zee; Gooitzen M van Dam
Journal:  Mol Imaging       Date:  2011-04-26       Impact factor: 4.488

4.  Exploiting Fluorescence Lifetime Plasticity in FLIM: Target Molecule Localization in Cells and Tissues.

Authors:  A Boreham; T-Y Kim; V Spahn; C Stein; L Mundhenk; A D Gruber; R Haag; P Welker; K Licha; U Alexiev
Journal:  ACS Med Chem Lett       Date:  2011-08-09       Impact factor: 4.345

5.  Synthesis and evaluation of a bimodal CXCR4 antagonistic peptide.

Authors:  Joeri Kuil; Tessa Buckle; Hushan Yuan; Nynke S van den Berg; Shinya Oishi; Nobutaka Fujii; Lee Josephson; Fijs W B van Leeuwen
Journal:  Bioconjug Chem       Date:  2011-04-19       Impact factor: 4.774

Review 6.  Fluorescent approaches for understanding interactions of ligands with G protein coupled receptors.

Authors:  Rajashri Sridharan; Jeffrey Zuber; Sara M Connelly; Elizabeth Mathew; Mark E Dumont
Journal:  Biochim Biophys Acta       Date:  2013-09-18

7.  Immunohistochemical detection of the CXCR4 expression in tumor tissue using the fluorescent peptide antagonist Ac-TZ14011-FITC.

Authors:  Nynke S van den Berg; Tessa Buckle; Joeri Kuil; Jelle Wesseling; Fijs W B van Leeuwen
Journal:  Transl Oncol       Date:  2011-08-01       Impact factor: 4.243

8.  Mapping the ligand-binding site on a G protein-coupled receptor (GPCR) using genetically encoded photocrosslinkers.

Authors:  Amy Grunbeck; Thomas Huber; Pallavi Sachdev; Thomas P Sakmar
Journal:  Biochemistry       Date:  2011-04-07       Impact factor: 3.162

9.  Structural and Biological Characterizations of Novel High-Affinity Fluorescent Probes with Overlapped and Distinctive Binding Regions on CXCR4.

Authors:  Siyu Zhu; Qian Meng; Robert T Schooley; Jing An; Yan Xu; Ziwei Huang
Journal:  Molecules       Date:  2019-08-13       Impact factor: 4.411

10.  Hybrid peptide dendrimers for imaging of chemokine receptor 4 (CXCR4) expression.

Authors:  Joeri Kuil; Tessa Buckle; Joppe Oldenburg; Hushan Yuan; Alexander D Borowsky; Lee Josephson; Fijs W B van Leeuwen
Journal:  Mol Pharm       Date:  2011-11-15       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.